



Concordant Results of Epidermal Growth Factor Receptor Mutation Detection by Real-Time Polymerase Chain Reaction and Ion Torrent Technology in Non-Small Cell Lung Cancer

Satu Mäki-Nevala¹, Aija Knuutila², Sakari Knuutila¹ and Virinder Kaur Sarhadi^{1*}

¹University of Helsinki, Faculty of Medicine, Medicum, Department of Pathology, P.O. Box 21, FI-00014 University of Helsinki, Finland

²University of Helsinki and Helsinki University Hospital, Heart and Lung Center, Department of Pulmonary Medicine, PO Box 340, FI-00029 Helsinki, Finland

Abstract

Nowaday screening of non-small cell lung cancer (NSCLC) patients for epidermal growth factor receptor (*EGFR*) activating mutations is carried out in routine diagnostics to select patients who could benefit from *EGFR* inhibitor therapies. We aimed to compare *EGFR* mutation testing by Ion Torrent PGM technology, using AmpliSeq Colon and Lung Cancer panel, with real-time PCR in order to evaluate the accuracy of next generation sequencing (NGS) in detecting clinically relevant *EGFR* mutations in NSCLC.

In total, 368 NSCLC patient samples were tested for *EGFR* by PCR and were also sequenced by Ion Torrent PGM by using AmpliSeq Colon and Lung panel. Samples were formalin-fixed, paraffin-embedded tumor specimens of Finnish NSCLC patients. The mutations studied for comparison were G719X, S768I, T790M, L858R, L861Q, deletions in exon 19 and insertions in exon 20.

Comparison of *EGFR* mutations detectable by both PCR kit and NGS panel, showed a high degree of concordance between the two methods. Out of 368 samples, 31 out of 32 positive by PCR were also positive by NGS, and 336 out of 336 negative by PCR for these mutations were also negative by NGS giving a concordance of 99.7%. Two negative samples by PCR showed insertions in exon 20, which were not detectable by PCR. In one sample NGS failed to detect G719X mutation that had a very weak signal in PCR.

Our study shows that the Ion Torrent PGM technology gives highly comparable results with the golden standard PCR. Thus, this NGS methodology is sensitive and reliable while testing clinically and diagnostically significant *EGFR* mutations in FFPE samples.

Keywords: Non-small cell lung cancer; Epidermal growth factor receptor; Mutation; Next generation sequencing; Ion Torrent; PCR

Introduction

The differences in molecular features of tumors and their predictive role in the response to targeting treatment have become very evident in the last decade. The alterations can be divided into groups based on a type of study they are approached with: protein, RNA and DNA-based methods. The last is used to assess mutations in the genome. In 2004, activating *EGFR* mutations and their role in the response to *EGFR* tyrosine kinase inhibitors (TKI) were described [1-3]. Since then many driver mutations in multiple genes, such as in *ALK*, and *RAS* and *HER* family, have been described, but *EGFR* mutations are still among the most common biomarkers in non-small-cell lung cancer (NSCLC). Currently the US Food and Drug Administration (FDA) has approved three different targeted therapies, afatinib, erlotinib and gefitinib, for advanced NSCLC harboring activating mutations most importantly *EGFR* exon 19 deletions or exon 21 substitution L858R [4].

There are also some other *EGFR* mutations with a clinical interest, such as G719X, L861Q and S768I, which have been associated with a good or partial response to *EGFR*-TKIs [5,6]. However, the development of resistance to *EGFR*-TKIs is common in the course of treatment. For instance, the acquired *EGFR* mutation T790M or *MET* amplification can cause the insensitivity to *EGFR*-TKIs after the preliminary good response [7-9]. Also insertions in exon 20 involving the residues A767, S768, D770, P772 and H773 show lack of response when treated with gefitinib or erlotinib [5,10]. Thus, it would be important to test patients' genetic alterations with the multiplex and sensitive methods.

PCR-based mutation testing kits and Sanger sequencing have become as golden standard methods for diagnostic purposes. Next generation sequencing (NGS) methods are fast, economical, sensitive and multiplexable, and they are slowly replacing the traditional methods. However, before implementation of NGS in diagnostic settings, it is important to thoroughly test and compare results to those with standard routine diagnostic methods. Some previous studies have shown the Ion Torrent PGM system to be accurate in mutation analysis by using the Ion AmpliSeq Colon and Lung cancer Panel and/or the Ion AmpliSeq Colon and Lung Cancer Research Panel V2 compared with Sanger sequencing [11,12], the Ion AmpliSeq™ Cancer Panel compared with direct sequencing of peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA PCR) product [13] and custom panel of cancer genes compared with Sanger sequencing [14], although these have been performed on smaller sample sizes. In this study, we

***Corresponding author:** Virinder Kaur Sarhadi, Ph.D., University of Helsinki, Faculty of Medicine, Medicum, Department of Pathology, P. O. Box 21 (Haartmaninkatu 3), FI-00014 University of Helsinki, Finland, Tel: +358 50 4482809; Fax: +358 2941 26527; E-mail: virinder.sarhadi@helsinki.fi

Received January 09, 2016; **Accepted** February 11, 2016; **Published** February 15, 2016

Citation: Mäki-Nevala S, Knuutila A, Knuutila S, Sarhadi VK (2016) Concordant Results of Epidermal Growth Factor Receptor Mutation Detection by Real-Time Polymerase Chain Reaction and Ion Torrent Technology in Non-Small Cell Lung Cancer. J Clin Respir Dis Care 2: 107. doi: [10.4172/JCRDC.1000107](https://doi.org/10.4172/JCRDC.1000107)

Copyright: © 2016 Mäki-Nevala S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

compared the *EGFR* mutation statuses of 368 Finnish NSCLC tumor specimens detected by the real-time PCR method and the targeted amplicon-based Ion Torrent NGS by using the Colon and Lung Cancer Panel performed on DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor material in order to evaluate the accuracy of NGS in detecting clinically important *EGFR* mutations.

Material and Methods

Patients

In total, we collected retrospectively 566 FFPE tumor specimens obtained via either diagnosis or surgical procedures, of NSCLC patients treated at the Hospital District of Helsinki and Uusimaa (HUS), Finland, during 2006–2014. Of those, tumor DNA from 368 NSCLC specimens were studied for *EGFR* mutations by both the real-time PCR and the amplicon-based NGS using the Colon and Lung Cancer Panel with the Ion Torrent PGM sequencing technology. Tumor content and histological type of NSCLC were confirmed by pathologist. Tumor content ranged from 5 to 90%, in 90% of the samples, the content was at least 20%. Patient characteristics are presented in the table 1.

DNA Extraction and Mutation Detection

DNA was isolated from FFPE sections using the QIAamp DNA Mini kit (Qiagen GmbH, Hilden, Germany), following the manufacturer's instructions, with small modifications [15]. DNA concentration was assessed using the Qubit® 2.0 Fluorometer (Thermo Fisher Scientific).

PCR Analysis

In our previous study, the tumor DNA samples of over 500 NSCLC patients were tested for *EGFR* mutations by using the Therascreen EGFR PCR Kit (Qiagen®, Manchester, UK) according to the manufacturer's protocol, on the ABI7500 platform or the cobas® *EGFR* Mutation Test (Roche Molecular Systems, South Branchburg, USA) according to the manufacturer's protocol, on the cobas® z480 platform [16]. Of those, 368 samples were studied also by Ion Torrent and in this study we compare the results.

Feature	N (%)
Histology	
ADC	265 (72)
SCC	58 (16)
LCC	28 (8)
ADSQ	11 (3)
Other NSCLC	6 (2)
Gender	
Male	211 (57)
Median age, years	66
Smoking^a	
Never-smoker	31 (8)
Light ex-smoker	29 (8)
Medium ex-smoker	133 (36)
Current smoker	170 (46)
NA	5 (1)
Abbreviations: ADC: Adenocarcinoma; LCC: Large Cell Carcinoma; SCC: Squamous Cell Carcinoma; ADSQ: Adenosquamous Carcinoma; NSCLC: Non-Small Cell Lung Cancer	
^a light ex-smoker: smoking <20 years, cessation >10 years ago; medium ex-smoker: smoking >20 years, ceased; and current smoker: current smokers, smoking >20 years	

Table 1: The characteristics of the patients included into this study.

Ion Torrent AmpliSeq Sequencing

Ten nanogram of DNA were used to prepare the barcoded libraries with the Ion AmpliSeq™ Library kit 2.0 (Thermo Fisher Scientific). The Colon and Lung Cancer panel covered 504 mutational hotspots and targeted regions (totaling 14.6 kb) in 22 genes, including *EGFR*. Template preparation and enrichment was performed with the Ion OneTouch™ 2 System (Thermo Fisher Scientific). Finally, sequencing was carried out using Ion 316™ chips on the Ion Personal Genome Machine System (PGM™, Thermo Fisher Scientific) and with the Ion PGM™ Sequencing 200 kit v2 (Thermo Fisher Scientific).

Alignment to the hg19 human reference genome and variant calling was performed by the Torrent Suite Software v.4.0.2 (Thermo Fisher Scientific) by the default threshold settings. For quality scores, coverage and strand biases those were a quality score of minimum of 6, relative read quality of minimum of 6.5, coverage of minimum of 6 for SNP/COSMIC variant and 15 for indel, and strand bias maximum of 95% for SNP/COSMIC variant and 90% for indel. Alignments were visually checked with the Integrative Genomics Viewer (IGV) (v.2.3.34, Broad Institute) [17].

Results & Discussion

We compared the *EGFR* mutation detection in 368 NSCLC FFPE tumor samples between the real-time PCR method and the amplicon-based Ion Torrent PGM sequencing technology (Tables 2 and 3). The mutations were detected in 9% (34/368) of the patients. The observed mutation status pattern was highly comparable with the results from other studies as illustrated in our previous study by the standard PCR [16]. We detected a very high concordance between the results by the two methods used. Comparing only those mutations detectable by PCR in 368 samples, 31 out of 32 positive by PCR were also positive by NGS, and 336 out of 336 negative by PCR for these mutations were also negative by NGS giving a concordance of 99.7%. When taking the PCR results as true positive, the number of *EGFR* positive by NGS, were 31 (true positive = 31; false positive = 0) and negative 337 (true negative = 336; false negative = 1). The sensitivity and specificity of detecting clinically common mutations L858R, deletions in exon 19, insertions in exon 20, G719X, S768I by the Ion AmpliSeq Colon and Lung Cancer Panel as following: 96.9% and 100%, respectively.

Other studies carried on relatively smaller sample size have shown a good concordance between PCR and NGS mutation testing [15,18,19]. Our results from a larger cohort clearly indicate that clinically important *EGFR* mutations can be detected with high accuracy by amplicon based NGS and is suitable in diagnostics. Similarly, recent comparisons between Sanger sequencing and NGS have shown similar results, giving greater sensitivity to NGS [11, 12, 15, 18-20]. Studies comparing the Ion

Mutation	Detected by PCR	Detected by NGS
L858R	15	15
Deletion in exon 19	12	12
G719X	4	3
G719X & S768I	1	1
Insertion in exon 20	0	2 ^a
Other COSMIC mutation ^a	0	12
No mutations	336	322
Total	368	368
^a Not detectable by Therascreen EGFR mutation testing.		

Table 2: The comparison of *EGFR* mutation result between PCR and AmpliSeq colon and lung panel.

S. No	Patient	Mutation by PCR	Mutation by NGS	Mutant read frequency, % (NGS)	Tumor content, %
1	359	L858R	L858R	14	20
2	66	L858R	L858R	37	55
3	505	L858R	L858R	6	20
4	546	L858R	L858R	74	45
5	203	L858R	L858R	25	40
6	217	L858R	L858R	5	35
7	157	L858R	L858R	10	40
8	160	L858R	L858R	30	55
9	105	L858R	L858R	21	35
10	27	L858R	L858R	16	30
11	560	L858R	L858R	11	30
12	554	L858R	L858R	3	10
13	486	L858R	L858R	44	60
14	671	L858R	L858R	17	70
15	603	L858R	L858R	3	10
16	233	Del Ex19	Del Ex19	60	35
17	199	Del Ex19	Del Ex19	34	50
18	508	Del Ex19	Del Ex19	31	65
19	215	Del Ex19	Del Ex19 ^a	10	30
20	52	Del Ex19	Del Ex19	10	35
21	211	Del Ex19	Del Ex19	55	70
22	70	Del Ex19	Del Ex19	33	45
23	631	Del Ex19	Del Ex19 ^b	28	55
24	653	Del Ex19	Del Ex19	12	15
25	587	Del Ex19	Del Ex19	26	60
26	646	Del Ex19	Del Ex19	54	70
27	632	Del Ex19	Del Ex19	18	10
28	239	G719X	G719X	42	55
29	107	G719X	no mutation ^c	0	70
30	234	G719X	G719X	37	50
31	688	G719X	G719A	37	30
32	672	G719X; S768I	G719A; S768I	12; 11	45
33	166	No mutation ^d	D770_N771insSVD	24	75
34	580	No mutation ^d	D770_N771insSVD	23	30
35	513	No mutation	S720F; A767V	3; 6	60
36	467	No mutation	V774M	8	45
37	350	No mutation	S784F	3	40
38	236	No mutation	A864T	2	70
39	34	No mutation	A864T	3	60
40	311	No mutation	D770N	3	15
41	521	No mutation	P741L	3	25
42	534	No mutation	V765M	2	70
43	344	No mutation	A871T	4	90
44	244	No mutation	A871T; G874S	4; 4	50
45	674	No mutation	R776H	3	40

^aMissed by Ion Torrent Software, but seen clearly by visualization in 9.9% of the reads.

^bNovel 2bp deletion followed by 10bp deletion.

^cDetected by Therascreen, but is uncertain with weak signal.

^dNot detectable by Therascreen EGFR mutation testing kit.

Table 3: The patients with EGFR mutations detected by either method.

Torrent technology are also in concordance with this study, suggesting it to be eligible method in diagnostics [11,12,19].

The comparison of the two methods showed discrepant results in two samples. One patient with *EGFR* deletion by PCR, was missed by the Ion Torrent software (probably filtered out by the variant calling setting), although it was clearly seen in 10% of reads with IGV. Another patient with G719X mutation in PCR was clearly negative for this

mutation by NGS even though the read depth at this location was 2204x. Since, this sample had a very low concentration in PCR (Ct 38.97 and dCt 11.70) and was flagged as doubtful; it is not certain whether it is false positive in PCR or false negative in NGS.

One important parameter of considerable significance in detecting mutations in tumor samples by NGS is deciding appropriate cut-off for mutation allele frequency, so as it maximizes sensitivity and minimizes

false positive rate. Since the proportion of tumor cells in tumor samples can vary greatly among different samples, it can greatly affect the mutant allele proportion. We therefore also analyzed the tumor content of sample, as estimated histologically, in relation to percent of mutant allele among total reads. Overall, the percentage of mutant reads ranged between 3 and 75% (average 28%) for all *EGFR* mutation. In this study, we could successfully detect *EGFR* mutations in samples with tumor content of 10% that had mutant reads percentage ranging between 3 and 18. At a cut-off of 3% for reads with mutant allele, we could detect all clinically relevant mutations without any false positives. This suggests NGS to be a sensitive method and can detect mutant alleles as low as 3% of the reads without false positives. Previous study has reported the limit of detection 1.3% or less for the Ion Torrent AmpliSeq panel [20]. Percentage of mutant reads was positively co-related to tumor percentage, though not very strongly (Pearson's correlation $R=0.5$). At least five samples had mutant reads more than 50% that could indicate a probable amplification of the mutant *EGFR* allele.

In addition to *EGFR* mutations that could be detected by both PCR and NGS, 12 patients had other COSMIC mutations detected by NGS, but not seen by PCR as they are not included in the PCR panel. This is a great advantage of NGS to detect all kind of mutations and distinguish them. By NGS, for instance, exon 19 deletions and exon 20 insertions are detectable in more detail, as PCR cannot distinguish them. By NGS we were able to identify two samples with exon 20 insertions (p.D770_N771insSVD) which were not detected by PCR, because it is not included in the PCR panel (Figure 1). Mutant reads were around 20% in both these cases by NGS. Similarly, we detected novel 2bp deletion in patient 631, which is not described previously. Although, this deletion was detected by PCR it did not identify it (since it only detects deletions without characterizing them). Moreover, we could clearly identify different variations of exon 19 deletion with NGS (Figure 2).

Another strength of the amplicon based Ion Torrent NGS is the sufficiency of small amount of starting material (ten nanogram of DNA), and its applicability to FFPE specimens. Moreover, Ion Torrent NGS workflow is user-friendly and fast.




Figure 1: IGV visualization of insertion P.D770_N771insSVD detected by NGS, but not by PCR.




Figure 2: IGV visualization of four different exon 19 deletions.

Conclusion

As conclusion, this study shows that the Ion Torrent technology gives highly comparable results with the golden standard PCR. Thus, this NGS methodology is sensitive and reliable while testing clinically and diagnostically important *EGFR* mutations from FFPE samples.

Acknowledgements

We are thankful to Milja Tikkanen and Tiina Wirtanen for the technical support. Grants: The study was funded by the Sigrid Jusélius Foundation, the Finnish Cancer Society, the Finnish Work Environment Fund and the Finnish Cultural Foundation.

References

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 350: 2129-2139.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 304: 1497-1500.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 101: 13306-13311.
4. Abramson R (2015) Overview of Targeted Therapies for Cancer. My Cancer Genome. <http://www.mycancergenome.org/content/molecular-medicine/overview-of-targeted-therapies-for-cancer> (accessed December 11, 2015).
5. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, et al. (2011) Effectiveness of tyrosine kinase inhibitors on «uncommon» epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. *Clin Cancer Res* 17: 3812-3821.
6. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, et al. (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol* 16: 830-838.
7. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 316: 1039-1043.
8. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 352: 786-792.
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2: e73.
10. Yasuda H, Kobayashi S, Costa DB (2012) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. *Lancet Oncol* 13: e23-31.

11. Belardinilli F, Capalbo C, Buffone A, Petroni M, Colicchia V, et al. (2015) Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. *Clin Biochem* 48: 908-910.
12. Malapelle U, Vigliar E, Sgariglia R, Bellevicine C, Colarossi L, et al. (2015) Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. *J Clin Pathol* 68: 64-68.
13. Kim HS, Sung JS, Yang SJ, Kwon NJ, Jin L, et al. (2013) Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma. *PLoS One* 8: e81975.
14. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, et al. (2013) Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. *J Mol Diagn* 15: 234-247.
15. Tuononen K, Mäki-Nevala S, Sarhadi VK, Wirtanen A, Ronty M, et al. (2013) Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. *Genes Chromosomes Cancer* 52: 503-511.
16. Mäki-Nevala S, Ronty M, Morel M, Gomez M, Dawson Z, et al. (2014) Epidermal growth factor receptor mutations in 510 Finnish non-small-cell lung cancer patients. *J Thorac Oncol* 9: 886-891.
17. Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* 14: 178-192.
18. Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, et al. (2014) Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. *Clin Chem Lab Med* 52: 707-714.
19. Fujita S, Masago K, Takeshita J, Okuda C, Otsuka K, et al. (2015) Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer. *PLoS One* 10: e0130219.
20. Lin MT, Mosier SL, Thiess M, Beierl KF, Debeljak M, et al. (2014) Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. *Am J Clin Pathol* 141: 856-866.